MedTrace Logo

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

NCT00142168 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2016-04-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the number of patients with Waldenstrom's macroglobulinemia that will benefit from treatment with CC-5103 (lenalidomide) and rituximab, what the side effects are and how long the benefit will last.

Conditions

  • Waldenstrom's Macroglobulinemia

Interventions

DRUG

CC-5103 (lenalidomide)

Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)

DRUG

Rituximab

Begins on week 2 of treatment and is given intravenously once a week for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Steven Treon, MD, MA, PhD · Dana-Farber Cancer Insitute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2006-05-31
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00142168 on ClinicalTrials.gov